Obinutuzumab activates FcγRI more potently than other anti-CD20 antibodies in chronic lymphocytic leukemia (CLL)
Sign Up to like & getrecommendations! Published in 2018 at "Oncoimmunology"
DOI: 10.1080/2162402x.2018.1428158
Abstract: ABSTRACT Treatment with monoclonal antibodies has revolutionized clinical medicine, especially in the fields of cancer and immunology. One of the oldest antibodies, which is widely used for the treatment of lymphomas and autoimmune diseases, is… read more here.
Keywords: anti cd20; lymphocytic leukemia; cd20 antibodies; leukemia cll ... See more keywords
Chicken‐derived CD20 antibodies with potent B‐cell depletion activity
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18438
Abstract: We report four novel anti‐human CD20 (hCD20) monoclonal antibodies (mAbs) discovered from a phylogenetically distant species—chickens. The chicken–human chimaeric antibodies exhibit at least 10‐fold enhanced antibody‐dependent cellular cytotoxicity (ADCC) and 4–8‐fold stronger complement‐dependent cytotoxicity (CDC)… read more here.
Keywords: cell; cd20 antibodies; cell depletion; depletion ... See more keywords
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies
Sign Up to like & getrecommendations! Published in 2017 at "Haematologica"
DOI: 10.3324/haematol.2017.169334
Abstract: Acalabrutinib is a new, irreversible Bruton tyrosine kinase (BTK) inhibitor, reported to be more selective than ibrutinib.[1][1]–[3][2] BTK inhibitors are often combined with anti-CD20 antibodies in the clinic, but ibrutinib interferes with some of the… read more here.
Keywords: cd20 antibodies; bruton tyrosine; tyrosine kinase;